Gilead Sciences | GILD - Trade Creditors


Gilead Sciences reported $645M in Trade Creditors for its fiscal quarter ending in March of 2026.





Trade Creditors Change Date
AbbVie USD 3.59B 28.65B Dec/2025
Agios Pharmaceuticals USD 16.34M 2.6M Jun/2026
ALKERMES USD 142.86M 40.5M Jun/2026
Alnylam Pharmaceuticals USD 108.02M 18.61M Jun/2026
Amgen USD 2.86B 16.65B Jun/2026
Biogen USD 403.9M 45.4M Jun/2026
BioMarin Pharmaceutical USD 913.67M 120.52M Jun/2026
Bristol-Myers Squibb USD 4.16B 76M Jun/2026
Coherus Biosciences USD 13.17M 1.69M Jun/2026
Eli Lilly USD 6.11B 1.08B Jun/2026
Gilead Sciences USD 645M 70M Mar/2026
GlaxoSmithKline GBP 14.34B 7M Jun/2026
Glaxosmithkline GBP 14.34B 6.39B Mar/2026
Incyte USD 1.39B 1.16B Jun/2026
J&J USD 9.22B 1.24B Jun/2026
Merck USD 3.83B 36M Jun/2026
Moderna USD 167M 6M Jun/2026
Neurocrine Biosciences USD 691.3M 145.8M Mar/2026
Novartis USD 4.26B 64M Jun/2026
Pfizer USD 4.58B 75M Jun/2026
PTC Therapeutics USD 40.45M 14.96M Jun/2026
Puma Biotechnology USD 6.39M 962K Sep/2025
Regeneron Pharmaceuticals USD 1.16B 132.2M Jun/2026
Sangamo BioSciences USD 10.74M 7.46M Jun/2025
Sanofi EUR 23.6B 888M Jun/2026
Sarepta Therapeutics USD 50.98M 19.39M Jun/2026
United Therapeutics USD 497.8M 500K Jun/2026
Vertex Pharmaceuticals USD 3.61B 135M Jun/2026